| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2eb708c6c80673271bd975b9a0665b9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96494
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54306
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54313
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-12 |
| filingDate |
2019-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17e026981e7bf746c1d91e6928a7f50f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a15507da36106816c1581a2b55119f52 |
| publicationDate |
2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3802852-A1 |
| titleOfInvention |
Engineered cyclic peptides |
| abstract |
An engineered cyclic peptide provides structural constraints to resist non-specific degradation in the human body and includes environment- specific cleavage sites to allow release of a linearized peptide upon reaching a target environment. The linearized peptide can include a reporter molecule or a bioactive therapeutic such that the cyclic peptide is essentially inactive at administration and in circulation but becomes reactive only upon exposure to target- specific environmental factors such as a specific combination of differentially-expressed proteases associated with a target tissue or disease state. The peptides can include tuning that modulate distribution by targeting the particle to specific tissue, bodily fluids, or cell types. |
| priorityDate |
2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |